Trial
NCT05025423
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
AbbVie
Condition
Mantle Cell Lymphoma
Intervention
Venetoclax Oral Tablet [Venclexta]
Why stopped
The study sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-10